{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:55:55Z","timestamp":1792788955991,"version":"4.5.0"},"reference-count":68,"publisher":"IMR Press","issue":"9","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Defense Congressionally Directed Medical Research Program","award":["OC230297"],"award-info":[{"award-number":["OC230297"]}],"id":[{"id":"https:\/\/ror.org\/03g2zjp07","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Science and Technology Innovation Joint Project of the Jiangxi Provincial Health Commission","award":["2025L3056"],"award-info":[{"award-number":["2025L3056"]}],"id":[{"id":"https:\/\/ror.org\/03vc7fb96","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Drug-tolerant persister (DTP) cells are a major cause of cancer treatment failure and tumor relapse. This review provides a systematic summary of recent advances in research on DTP cells in cancer, including their biological features, model systems, and targeting strategies. Current studies show that formation of DTP cells is a complex and dynamic process, involving cell cycle arrest, epigenetic remodeling, and extensive transcriptional and metabolic reprogramming. The drug tolerance of DTP cells arises from a cooperative molecular network that integrates metabolic adaptation, reactivation of key signaling pathways, and resistance to cell death programs. To investigate the DTP state, researchers have developed a variety of in vitro and in vivo models, including patient-derived xenograft (PDX) models, drug-treated cancer cell lines, and organoid systems. These models have become essential tools for identifying vulnerabilities in DTP cells, such as sensitivity to ferroptosis induction, dependence on specific metabolic pathways, and expression of distinct surface antigens. However, the field still faces important challenges. Existing models have limitations in mimicking the complex tumor microenvironment and in capturing the transient nature of DTP cells. In addition, the clinical value of targeting strategies identified with experimental models remains to be validated in large-scale trials. The high level of heterogeneity of DTP cells and the lack of standardized research protocols also hinder the comparison and integration of findings across studies. The future development of more physiologically relevant models, the use of advanced technologies to better characterize DTP cells, and the design of clinical trials aimed at eliminating DTP cells are critical steps in the transition from tumor control to durable cure.<\/jats:p>","DOI":"10.31083\/fbl49637","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:21:51Z","timestamp":1790698911000},"source":"Crossref","is-referenced-by-count":0,"title":["Targeting Drug-Tolerant Persister Cells in Cancer: Progress From Modeling to Targeting Fragility Studies"],"prefix":"10.31083","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1645-5445","authenticated-orcid":true,"given":"Yanping","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Gynecological Oncology, Jiangxi Maternal and Child Health Hospital, 330006 Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4585-2211","authenticated-orcid":true,"given":"Xuqing","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, Jiangxi Maternal and Child Health Hospital, 330006 Nanchang, Jiangxi, China"},{"name":"Jiangxi Key Laboratory of Cervical Cancer, Jiangxi Maternal and Child Health Hospital, 330006 Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-6617","authenticated-orcid":true,"given":"Yufang","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, Jiangxi Maternal and Child Health Hospital, 330006 Nanchang, Jiangxi, China"},{"name":"Jiangxi Key Laboratory of Cervical Cancer, Jiangxi Maternal and Child Health Hospital, 330006 Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4744-8374","authenticated-orcid":true,"given":"Jeremy R","family":"Chien","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA 95616, USA"},{"name":"Department of Obstetrics and Gynecology, University of California, Davis, Sacramento, CA 95616, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7142-9371","authenticated-orcid":true,"given":"Meirong","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, Jiangxi Maternal and Child Health Hospital, 330006 Nanchang, Jiangxi, China"},{"name":"Jiangxi Key Laboratory of Cervical Cancer, Jiangxi Maternal and Child Health Hospital, 330006 Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010; 141: 69\u201380.","DOI":"10.1016\/j.cell.2010.02.027"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Mikubo M, Inoue Y, Liu G, Tsao MS. Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. 2021; 16: 1798\u20131809.","DOI":"10.1016\/j.jtho.2021.07.017"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Pu Y, Li L, Peng H, Liu L, Heymann D, Robert C, et al. Drug-tolerant persister cells in cancer: the cutting edges and future directions. Nature Reviews. Clinical Oncology. 2023; 20: 799\u2013813.","DOI":"10.1038\/s41571-023-00815-5"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Rodriguez R, Schreiber SL, Conrad M. Persister cancer cells: Iron addiction and vulnerability to ferroptosis. Molecular Cell. 2022; 82: 728\u2013740.","DOI":"10.1016\/j.molcel.2021.12.001"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Zhang W, Chattrakarn S, Chen F, Chai H, Maranga M, Zhang J. Targeting Cancer Drug-Tolerant Persister Cells in Minimal Residual Disease. International Journal of Drug Discovery and Pharmacology. 2025; 4: 100011.","DOI":"10.53941\/ijddp.2025.100011"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Wang Z, Wang M, Dong B, Wang Y, Ding Z, Shen S. Drug-tolerant persister cells in cancer: bridging the gaps between bench and bedside. Nature Communications. 2025; 16: 10048.","DOI":"10.1038\/s41467-025-66376-6"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Bhang HEC, Ruddy DA, Krishnamurthy Radhakrishna V, Caushi JX, Zhao R, Hims MM, et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nature Medicine. 2015; 21: 440\u2013448.","DOI":"10.1038\/nm.3841"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017; 551: 247\u2013250.","DOI":"10.1038\/nature24297"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"He J, Qiu Z, Fan J, Xie X, Sheng Q, Sui X. Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies. Signal Transduction and Targeted Therapy. 2024; 9: 209.","DOI":"10.1038\/s41392-024-01891-4"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Zhou M, Haga Y, Nishimura A, Tanahashi S, Higashisaka K, Tsutsumi Y. Cell cycle dynamics analysis of drug-tolerant persister cells in non-small cell lung cancer. Biochemical and Biophysical Research Communications. 2025; 775: 152107.","DOI":"10.1016\/j.bbrc.2025.152107"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Horwitz E, Dubash TD, Szabolcs A, Wittner BS, Kreuzer J, Morris R, et al. CDKN1B (p27\/kip1) enhances drug-tolerant persister CTCs by restricting polyploidy following mitotic inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 2025; 122: e2507203122.","DOI":"10.1073\/pnas.2507203122"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Peyre L, P\u00e9r\u00e9 M, Meyer M, Bian B, Moureau-Barbato M, Djema W, et al. Transition between cell states of sensitivity reveals molecular vulnerability of drug-tolerant cells. Molecular Systems Biology. 2025; 21: 1702\u20131730.","DOI":"10.1038\/s44320-025-00150-0"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Rosenbaum SR, Wilski NA, Aplin AE. Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy. Cancer Discovery. 2021; 11: 266\u2013281.","DOI":"10.1158\/2159-8290.CD-20-0805"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Xue X, Li Z, Zhao J, Zhao Z, Li Z, Li Y, et al. Advances in the relationship between AP-1 and tumorigenesis, development and therapy resistance. Discover Oncology. 2025; 16: 61.","DOI":"10.1007\/s12672-025-01783-1"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Baudre L, Jouault G, Prompsy P, Saichi M, Gastineau S, Huret C, et al. Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients. Cancer Research. 2025; OF1\u2013OF16.","DOI":"10.1158\/0008-5472.CAN-25-0995"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"B\u00f6pple K, Oren Y, Henry WS, Dong M, Weller S, Thiel J, et al. ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC. Cell Death & Disease. 2024; 15: 290.","DOI":"10.1038\/s41419-024-06674-x"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Kalkavan H, Chen MJ, Crawford JC, Quarato G, Fitzgerald P, Tait SWG, et al. Sublethal cytochrome c release generates drug-tolerant persister cells. Cell. 2022; 185: 3356\u20133374.e22.","DOI":"10.1016\/j.cell.2022.07.025"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Singh A, Gupta I, Saha P, Hole A, Anthony F, Natu A, et al. Raman spectroscopy for detecting gastric and liver cancer cells that entered a tolerant persistence state to survive cisplatin chemotherapy. Biochemical and Biophysical Research Communications. 2025; 790: 152891.","DOI":"10.1016\/j.bbrc.2025.152891"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Li Y, Chen H, Lu D, Koeffler HP, Zhang Y, Yin D. Mitophagy is a novel protective mechanism for drug-tolerant persister (DTP) cancer cells. Autophagy. 2023; 19: 2618\u20132619.","DOI":"10.1080\/15548627.2023.2177398"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Garcia NMG, Becerra JN, McKinney BJ, DiMarco AV, Wu F, Fitzgibbon M, et al. APOBEC3 activity promotes the survival and evolution of drug-tolerant persister cells during acquired resistance to EGFR inhibitors in lung cancer. bioRxiv. 2024.  (preprint)","DOI":"10.1101\/2023.07.02.547443"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Takahashi H, Sakakibara-Konishi J, Furuta M, Shoji T, Tsuji K, Morinaga D, et al. Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancer. Cancer Science. 2023; 114: 1635\u20131650.","DOI":"10.1111\/cas.15674"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Rehman SK, Haynes J, Collignon E, Brown KR, Wang Y, Nixon AML, et al. Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy. Cell. 2021; 184: 226\u2013242.e21.","DOI":"10.1016\/j.cell.2020.11.018"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Shen S, Vagner S, Robert C. Persistent Cancer Cells: The Deadly Survivors. Cell. 2020; 183: 860\u2013874.","DOI":"10.1016\/j.cell.2020.10.027"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Li H, Xu W, Cheng W, Yu G, Tang D. Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategies. Frontiers in Pharmacology. 2025; 16: 1612089.","DOI":"10.3389\/fphar.2025.1612089"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Zhang Y, Zhang X, Yang X, Chen X, Wang Y, Hu J, et al. EGFR-TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). 2025; 12: e06950.","DOI":"10.1002\/advs.202506950"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Zhang W, Lang J, Chattrakarn S, Wong CW, Li S, Kan K, et al. NRF2-mediated persistent adaptation of oesophageal adenocarcinoma cells to HER2 inhibition. Oncogene. 2025; 44: 2929\u20132941.","DOI":"10.1038\/s41388-025-03459-0"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Zhang Z, Qin S, Chen Y, Zhou L, Yang M, Tang Y, et al. Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy. EMBO Molecular Medicine. 2022; 14: e14903.","DOI":"10.15252\/emmm.202114903"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Jog E, Jainarayanan AK, La Ferlita A, Chakraborty A, Dalwai A, Yahya S, et al. Inhibiting de novo lipogenesis identifies a therapeutic vulnerability in therapy-resistant colorectal cancer. Redox Biology. 2025; 79: 103458.","DOI":"10.1016\/j.redox.2024.103458"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Cheng YC, Chen MY, Yadav VK, Pikatan NW, Fong IH, Kuo KT, et al. Targeting FABP4\/UCP2 axis to overcome cetuximab resistance in obesity-driven CRC with drug-tolerant persister cells. Translational Oncology. 2025; 53: 102274.","DOI":"10.1016\/j.tranon.2025.102274"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Chuang HY, Cheng CH, Guo F, Yadav VK, Fong IH, Lin JW, et al. Super-enhancer PPP1R15B\/EIF2A axis characterizes aggressive drug-tolerant persister cells in Glioblastoma. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2025; 189: 118309.","DOI":"10.1016\/j.biopha.2025.118309"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Hsu HE, Martin MJ, Weng SH, Kitata RB, Nagelli S, Chang CY, et al. Phosphoproteomics of osimertinib-tolerant persister cells reveals targetable kinase-substrate signatures. Molecular Systems Biology. 2025; 21: 1547\u20131562.","DOI":"10.1038\/s44320-025-00141-1"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Chaudhary N, Choudhary BS, Shivashankar A, Manna S, Ved K, Shaikh S, et al. EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI. Cancer Cell International. 2025; 25: 55.","DOI":"10.1186\/s12935-025-03691-4"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Haderk F, Chou YT, Cech L, Fern\u00e1ndez-M\u00e9ndez C, Yu J, Olivas V, et al. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nature Communications. 2024; 15: 3741.","DOI":"10.1038\/s41467-024-47423-0"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Oren Y, Tsabar M, Cuoco MS, Amir-Zilberstein L, Cabanos HF, H\u00fctter JC, et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature. 2021; 596: 576\u2013582.","DOI":"10.1038\/s41586-021-03796-6"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Bellio C, Emperador M, Castellano P, Gris-Oliver A, Canals F, S\u00e1nchez-Pla A, et al. GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells. Cancers. 2022; 14: 2562.","DOI":"10.3390\/cancers14102562"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Smalley M, Natarajan SK, Mondal J, Best D, Goldman D, Shanthappa B, et al. Nanoengineered Disruption of Heat Shock Protein 90 Targets Drug-Induced Resistance and Relieves Natural Killer Cell Suppression in Breast Cancer. Cancer Research. 2020; 80: 5355\u20135366.","DOI":"10.1158\/0008-5472.CAN-19-4036"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Baldacci S, Brea EJ, Facchinetti F, Li Z, Ngo K, Malhotra S, et al. Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy. Cancer Discovery. 2025; 15: 2235\u20132250.","DOI":"10.1158\/2159-8290.CD-24-1515"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Xie C, Wu J, Yang H, Gu A, Cao W, Yao X, et al. GSCs differentiation model-informed nanotherapy: dual-functional brain-targeting liposomes with iRGD modification for co-delivery of osimertinib and bortezomib to combat radioresistant glioblastoma. Cell Death & Disease. 2025; 16: 738.","DOI":"10.1038\/s41419-025-08083-0"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Wang Y, Zhao G, Condello S, Huang H, Cardenas H, Tanner EJ, et al. Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis. Cancer Research. 2021; 81: 384\u2013399.","DOI":"10.1158\/0008-5472.CAN-20-1488"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Ramirez M, Rajaram S, Steininger RJ, Osipchuk D, Roth MA, Morinishi LS, et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nature Communications. 2016; 7: 10690.","DOI":"10.1038\/ncomms10690"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Szeb\u00e9nyi K, F\u00fcredi A, Bajtai E, Sama SN, Csiszar A, Gombos B, et al. Effective targeting of breast cancer by the inhibition of P-glycoprotein mediated removal of toxic lipid peroxidation byproducts from drug tolerant persister cells. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 2023; 71: 101007.","DOI":"10.1016\/j.drup.2023.101007"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"du Manoir S, Delpech H, Orsetti B, Jacot W, Pirot N, Noel J, et al. In high-grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired-resistance derive from quiescent residual cancer cells that overexpress CRYAB, CEACAM6, and SOX2. The Journal of Pathology. 2022; 257: 367\u2013378.","DOI":"10.1002\/path.5896"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Zhou X, An J, Kurilov R, Brors B, Hu K, Peccerella T, et al. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Nature Cancer. 2023; 4: 1362\u20131381.","DOI":"10.1038\/s43018-023-00628-6"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Glasheen MQ, Caksa S, Young AG, Wilski NA, Ott CA, Chervoneva I, et al. Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma. Molecular Cancer Therapeutics. 2023; 22: 1087\u20131099.","DOI":"10.1158\/1535-7163.MCT-23-0025"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Rumde PH, Burns TF. A Path to Persistence after EGFR Inhibition. Cancer Research. 2024; 84: 1188\u20131190.","DOI":"10.1158\/0008-5472.CAN-24-0274"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Moghal N, Li Q, Stewart EL, Navab R, Mikubo M, D'Arcangelo E, et al. Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. 2023; 18: 499\u2013515.","DOI":"10.1016\/j.jtho.2022.12.003"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nature Medicine. 2016; 22: 262\u2013269.","DOI":"10.1038\/nm.4040"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Broderick C, Mezzadra R, Sisso EM, Mbuga F, Raghulan R, Chaves-Perez A, et al. A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma. Cancer Discovery. 2025; 15: 1717\u20131739.","DOI":"10.1158\/2159-8290.CD-24-1425"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Ishida T, Takahashi T, Kurokawa Y, Nishida T, Hirota S, Serada S, et al. Targeted therapy for drug-tolerant persister cells after imatinib treatment for gastrointestinal stromal tumours. British Journal of Cancer. 2021; 125: 1511\u20131522.","DOI":"10.1038\/s41416-021-01566-9"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Kaiser P, Regoes RR, Hardt WD. Population Dynamics Analysis of Ciprofloxacin-Persistent S. Typhimurium Cells in a Mouse Model for Salmonella Diarrhea. Methods in Molecular Biology (Clifton, N.J.). 2016; 1333: 189\u2013203.","DOI":"10.1007\/978-1-4939-2854-5_16"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Chen J, Liao S, Xiao Z, Pan Q, Wang X, Shen K, et al. The development and improvement of immunodeficient mice and humanized immune system mouse models. Frontiers in Immunology. 2022; 13: 1007579.","DOI":"10.3389\/fimmu.2022.1007579"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Wege AK, Ernst W, Eckl J, Frankenberger B, Vollmann-Zwerenz A, M\u00e4nnel DN, et al. Humanized tumor mice--a new model to study and manipulate the immune response in advanced cancer therapy. International Journal of Cancer. 2011; 129: 2194\u20132206.","DOI":"10.1002\/ijc.26159"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Lin H, Wang L, Chen H, Shen Y, Wang C, Xue Y, et al. Mitochondrial fatty acid oxidation as the target for blocking therapy-resistance and inhibiting tumor recurrence: The proof-of-principle model demonstrated for ovarian cancer cells. Journal of Advanced Research. 2026; 79: 571\u2013585.","DOI":"10.1016\/j.jare.2025.03.026"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Zhang ZY, Ding Y, Ezhilarasan R, Lhakhang T, Wang Q, Yang J, et al. Lineage-coupled clonal capture identifies clonal evolution mechanisms and vulnerabilities of BRAFV600E inhibition resistance in melanoma. Cell Discovery. 2022; 8: 102.","DOI":"10.1038\/s41421-022-00462-7"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Chen TM, Huang CM, Setiawan SA, Hsieh MS, Sheen CC, Yeh CT. KDM5D Histone Demethylase Identifies Platinum-Tolerant Head and Neck Cancer Cells Vulnerable to Mitotic Catastrophe. International Journal of Molecular Sciences. 2023; 24: 5310.","DOI":"10.3390\/ijms24065310"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Moser SC, Khalizieva A, Roehsner J, Pottendorfer E, Kaptein ML, Ricci G, et al. NASP modulates histone turnover to drive PARP inhibitor resistance. Nature. 2025; 645: 1071\u20131080.","DOI":"10.1038\/s41586-025-09414-z"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Wang R, Pan Y, Zhang L, Wang J, Ni J, Ding Y, et al. Prebiotic stachyose inhibits PRDX5 activity and castration-resistant prostate cancer development. International Journal of Biological Macromolecules. 2024; 278: 134844.","DOI":"10.1016\/j.ijbiomac.2024.134844"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Shi R, Farnsworth DA, Febres-Aldana CA, Chow JLM, Sheena R, Atwal T, et al. Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinoma. Oncogene. 2025; 44: 2831\u20132849.","DOI":"10.1038\/s41388-025-03461-6"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"van Gastel N, Spinelli JB, Sharda A, Schajnovitz A, Baryawno N, Rhee C, et al. Induction of a Timed Metabolic Collapse to Overcome Cancer Chemoresistance. Cell Metabolism. 2020; 32: 391\u2013403.e6.","DOI":"10.1016\/j.cmet.2020.07.009"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Cardenas H, Wang Y, Zhao G, Hao DX, Isac AM, Hernandez V, et al. Metabolic Dependency on De Novo Pyrimidine Synthesis Is a Targetable Vulnerability in Platinum-Resistant Ovarian Cancer. Cancer Research. 2026; 86: 387\u2013401.","DOI":"10.1158\/0008-5472.CAN-25-0043"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Wang W, Cai Q, Liu Y, Nie L, Lee HH, Yan F, et al. TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma. Blood. 2025; 146: 2544\u20132560.","DOI":"10.1182\/blood.2024026919"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, et al. Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell. 2019; 35: 851\u2013867.e7.","DOI":"10.1016\/j.ccell.2019.05.001"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Chen M, Mainardi S, Lieftink C, Velds A, de Rink I, Yang C, et al. Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse. Cell Reports. Medicine. 2024; 5: 101471.","DOI":"10.1016\/j.xcrm.2024.101471"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Marx V. Method of the Year: spatially resolved transcriptomics. Nature Methods. 2021; 18: 9\u201314.","DOI":"10.1038\/s41592-020-01033-y"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Hunter MV, Moncada R, Weiss JM, Yanai I, White RM. Spatially resolved transcriptomics reveals the architecture of the tumor-microenvironment interface. Nature Communications. 2021; 12: 6278.","DOI":"10.1038\/s41467-021-26614-z"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Satpathy AT, Granja JM, Yost KE, Qi Y, Meschi F, McDermott GP, et al. Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion. Nature Biotechnology. 2019; 37: 925\u2013936.","DOI":"10.1038\/s41587-019-0206-z"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Wu TD, Madireddi S, de Almeida PE, Banchereau R, Chen YJJ, Chitre AS, et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature. 2020; 579: 274\u2013278.","DOI":"10.1038\/s41586-020-2056-8"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Zhang Y, Chen H, Mo H, Hu X, Gao R, Zhao Y, et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021; 39: 1578\u20131593.e8.","DOI":"10.1016\/j.ccell.2021.09.010"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/9\/10.31083\/FBL49637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:22:39Z","timestamp":1790698959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/9\/10.31083\/FBL49637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":68,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2768-6701(26)02045-9"],"URL":"https:\/\/doi.org\/10.31083\/fbl49637","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"49637"}}